BRAF and cancer: Overall, these results suggest that ReKINect is capable of predicting NAMs that constitutively activate or inactivate protein kinases and that, in addition to BRAF V600E, numerous other similar mutations are likely to exist that directly affect the catalytic activity of kinases in cancer signaling.